39 research outputs found

    Cyclosporine-A์— ์˜ํ•œ ์‹ ๋…์„ฑ ์œ ๋ฐœ ์ฅ์—์„œ cGMP phosphodiesterase ์–ต์ œ์ œ๊ฐ€ eNOS์™€ VEGF์˜ ๋ฐœํ˜„์— ๋ฏธ์น˜๋Š” ์˜ํ–ฅ

    No full text
    ์˜ํ•™๊ณผ/๋ฐ•์‚ฌ[ํ•œ๊ธ€] [์˜๋ฌธ]Background: Cyclosporine-A (CsA) inhibits the differentiation of T cells by suppressing calcineurin and thus blocks the activation of the IL-2 promotor gene which blocks the rejection of kidney transplants and is an essential immune suppressor used after kidney transplantation. However, when CsA is used long term, nephrotoxicity develops. Hence, long term CsA use must be limited. The mechanism of CsA induced nephrotoxicity have been suggested vasoconstriction due to the reduction of nitric oxide (NO), and tissue fibrosis caused by the elevation of transforming growth factor (TGF)-beta, vascular endothelial growth factor (VEGF). The cyclic guanosine monophosphate (cGMP) phosphodiesterase (PDE) inhibitor (Udenafil, Zydenaยฎ), active in the NO/cGMP pathway, with its physiological function induced by cGMP, has been reported to ameliorate renal injury by the increase of cGMP through the suppression of cGMP-specific PDE-5. In this study, in a rat model of CsA-induced nephrotoxicity, the administration of the PDE-5 inhibitor udenafil was studied to determine whether it ameliorated kidney dysfunction and altered the expression of eNOS and VEGF.Methods: A right nephrectomy was performed in Sprague-Dawley rats (N=30, 200-250g, male). The Ischemia group (N=6), had ligation of the left renal artery for 45 minutes (IR) and was maintained for 28 days. The Udenafil group (N=6), after ischemia, was treated with 10 mg/kg udenafil orally for 28 days. The CsA group (N=6), after IR and then 15 mg/kg cyclosporine-A was injected subcutaneously for 28 days. The CsA with udenafil group (N=6), after IR received 15 mg/kg cyclosporine-A injected subcutaneously together with the oral administration of 10 mg/kg udenafil for 28 days. A low salt diet was provided to all groups. After the collection of blood on day 28, the remaining kidney was resected surgically and the injury was assessed by hematoxylin-eosin (H&E) staining, immunohistochemical staining, western blot, real time-PCR analysis was used to assess degree of renal injury and the expression of eNOS and VEGF.Results: The comparison with the Ischemia group and the CsA group, after the administration of udenafil, showed that the creatinine was significantly decreased (p=0.002, p=0.002, respectively). The H&E staining, comparing the Ischemia group and the CsA group, showed that the level of loss of the nuclei in the proximal tubules was significantly decreased after the administration of udenafil (p=0.004, p=0.002, respectively). The immunohistochemical staining showed that eNOS stained strongly in the Udenafil group and the CsA with udenafil group compared to the other groups. The results of the eNOS western blot showed that it was not changed in the Ischemia group; however, the expression of the protein was decreased in the CsA group, and increased in the Udenafil group. For the VEGF western blot, the expression of the protein was reduced only in the CsA with udenafil group. The eNOS mRNA assessed by real time-PCR was decreased in the CsA group compared to the other groups (p=0.000). VEGF mRNA was decreased in the CsA group, and after the administration of udenafil, it showed a tendency to decrease more (p=0.003, p=0.005, respectively).Conclusion: cGMP phosphodiesterase inhibitor ameliorated kidney injury in a rat model of CsA-induced nephrotoxicity. The mechanism appears to be associated with an increase of eNOS and reduction of VEGF.ope

    Clinical significance of B-type natriuretic peptide levels and impedance cardiography in maintenance hemodialysis patie

    No full text
    ์˜ํ•™๊ณผ/์„์‚ฌ[ํ•œ๊ธ€] ์ •๊ธฐ์  ํ˜ˆ์•กํˆฌ์„ ์น˜๋ฃŒ ์ค‘์ธ ํ™˜์ž์—์„œ ์œ ๋ณ‘๋ฅ ๊ณผ ์‚ฌ๋ง๋ฅ ์˜ ๊ฐ€์žฅ ๋งŽ์€ ๋ถ€๋ถ„์„ ์ฐจ์ง€ํ•˜๋Š” ์‹ฌํ˜ˆ๊ด€๊ณ„ ์งˆํ™˜์— ๋Œ€ํ•ด ํ‰๊ฐ€ํ•  ์ˆ˜ ์žˆ๋Š” ๋น„์นจ์Šต์ ์ธ ๋ฐฉ๋ฒ• ์ค‘์˜ ํ•œ๊ฐ€์ง€๋กœ ์•Œ๋ ค์ง„ B-type natriuretic peptide (BNP)์˜ ์ธก์ •์€ ํ˜ˆ์•กํˆฌ์„์„ ๋ฐ›๊ณ  ์žˆ๋Š” ํ™˜์ž๋“ค์˜ ์‹ฌ์žฅ๊ธฐ๋Šฅ ํ‰๊ฐ€์— ์ œํ•œ์ ์ธ ์š”์†Œ๋“ค์ด ๋งŽ์€ ๊ฒƒ์ด ์‚ฌ์‹ค์ด๋‹ค. ์ด์— ์ €์ž๋“ค์€ ๋น„์นจ์Šต์ ์ธ ๋ฐฉ๋ฒ•์œผ๋กœ ์‹ ์ฒด์˜ impedance๋ฅผ ์ด์šฉํ•˜์—ฌ cardiac index (CI)์™€ ๊ฐ™์€ ์‹ฌ์žฅ๊ธฐ๋Šฅ์„ ํ‰๊ฐ€ํ•˜๊ณ  BNP์™€ impedance cardiography (ICG)์™€์˜ ์—ฐ๊ด€์„ฑ ๋ฐ ์ž„์ƒ์  ์œ ์šฉ์„ฑ์— ๋Œ€ํ•ด ํ‰๊ฐ€ํ•˜์˜€๋‹ค.์ •๊ธฐ์ ์œผ๋กœ ํ˜ˆ์•กํˆฌ์„ ์น˜๋ฃŒ๋ฅผ ๋ฐ›๊ณ  ์žˆ๋Š” ํ™˜์ž 40๋ช… (๋‚จ์ž 18๋ช…, ์—ฌ์ž 22๋ช…)๊ณผ 10๋ช…์˜ ์ •์ƒ ๋Œ€์กฐ๊ตฐ์„ ๋Œ€์ƒ์œผ๋กœ ํ•˜์˜€์œผ๋ฉฐ ํ™˜์ž๊ตฐ์€ ๋ชจ๋‘ ํˆฌ์„ ์ „ํ›„์— BNP์™€ ICG๋ฅผ ์ธก์ •ํ•˜์—ฌ ๋น„๊ตํ•˜์˜€๋‹ค.1. BNP๋ฟ๋งŒ ์•„๋‹ˆ๋ผ ICG์˜ ์—ฌ๋Ÿฌ ์š”์†Œ๋“ค์ด ์ •์ƒ ๋Œ€์กฐ๊ตฐ์— ๋น„ํ•ด ํ™˜์ž๊ตฐ์—์„œ ์˜๋ฏธ์žˆ๊ฒŒ ๋†’์•˜๋‹ค (p<0.05).2. BNP, stroke index (SI), stroke volume (SV) ๋ฐ thoracic fluid content (TFC)๋Š” ํˆฌ์„ ํ›„์— ์˜๋ฏธ์žˆ๋Š” ๋ณ€ํ™”๋ฅผ ๋ณด์˜€๋‹ค(p<0.05).3. ๋‹น๋‡จ๊ตฐ์€ ํˆฌ์„์ „ BNP, ํˆฌ์„ํ›„ BNP, SI, SV ๋ฐ velocity index (VI) ๋“ฑ์ด ๋น„๋‹น๋‡จ๊ตฐ๊ณผ ์œ ์˜ํ•œ ์ฐจ์ด๋ฅผ ๋ณด์˜€๋‹ค(p<0.05).4. ํˆฌ์„์ „ BNP ์ธก์ •์น˜๋Š” ํˆฌ์„ํ›„ BNP, ์ˆ˜์ถ•๊ธฐ ํ˜ˆ์••, ํ™•์žฅ๊ธฐ ํ˜ˆ์••, cardiac output (CO), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI) ๋ฐ TFC ๋“ฑ๊ณผ ์˜๋ฏธ์žˆ๋Š” ์ƒ๊ด€๊ด€๊ณ„๋ฅผ ๋ณด์˜€๋‹ค(p<0.05).์ด์ƒ์˜ ๊ฒฐ๊ณผ๋กœ BNP์™€ ICG์˜ ์ธก์ •์€ ๋น„์นจ์Šต์ ์ธ ๋ฐฉ๋ฒ•์œผ๋กœ ์„œ๋กœ ์ƒํ˜ธ๋ณด์™„ ๊ธฐ๋Šฅ์„ ๊ฐ€์ง€๊ณ  ํ˜ˆ์•กํˆฌ์„์„ ๋ฐ›๊ณ  ์žˆ๋Š” ํ™˜์ž์˜ ์‹ฌ์žฅ๋ณ€ํ™”๋ฅผ ํ‰๊ฐ€ํ•  ์ˆ˜ ์žˆ๋Š” ์œ ์šฉํ•œ ์ง„๋‹จ๋„๊ตฌ๋กœ์จ ์ƒ๊ฐ๋˜๋ฉฐ ๋” ๋งŽ์€ ํ™˜์ž๋ฅผ ๋Œ€์ƒ์œผ๋กœ ํ•œ ์—ฐ๊ตฌยท๊ฒ€ํ† ๊ฐ€ ํ•„์š”ํ•  ๊ฒƒ์œผ๋กœ ์ƒ๊ฐ๋œ๋‹ค. [์˜๋ฌธ]The risk for cardiovascular morbidity and mortality is higher in hemodialysis (HD) patients than in general population. Early diagnosis, treatment and prevention of cardiovascular disease (CVD) are the best way to reduce the most important cause of death. However, cardiac geometric and/or functional alterations including left ventricular hypertrophy, atherosclerosis and/or systolic and diastolic dysfunction are not easily known to nephrologist in that diagnostic procedure is limited because cardiac angiography and echocardiography are frequently needed.To evaluate the cardiac alteration by non-invasive tools, we measured pre- and post-HD B-type natriuretic peptide levels and performed impedance cardiography (ICG) in 40 HD patients and 10 healthy adults as control.Pre- and post-HD BNP level, cardiac index (CI), cardiac output (CO), stroke volume (SV), systemic vascular resistance index (SVRI), systemic vascular resistance (SVR), acceleration index (ACI), velocity index (VI) and thoracic fluid content (TFC) in patients were significantly higher than those in normal control group (p<0.05). Pre-HD BNP level, stroke index (SI), SV and TFC were significantly different after HD (p<0.05). There were significant differences in pre-HD BNP level, SI, SV and VI between diabetes and non-diabetes groups (p<0.05). Pre-HD BNP level correlated significantly with post-HD BNP level, systolic blood pressure, diastolic blood pressure, CO, SVRI, SVR and TFC (P<0.05). In multiple linear regression analysis, SVR and TFC were positively associated with pre-HD BNP level (R2 = 0.289). The area under the ROC curve for cardiac alterations was 0.749 for pre-HD BNP level. A cutoff-point of 560 pg/mL for pre-HD BNP level was 80% sensitive and 72% specific in determining cardiac alterations.Even though cardiac alterations of patients were heterogeneous in our study, serum BNP level and some parameters (SVR, TFC) of ICG seem to be available to nephrologist for detecting and monitoring cardiac conditions in HD patients.ope

    ํ•œ๊ตญ ์ผ๋ฐ˜ ์„ฑ์ธ ์ธ๊ตฌ์—์„œ์˜ ์ธ์Š๋ฆฐ ์ €ํ•ญ์„ฑ๊ณผ ๊ณจ๋ฐ€๋„, ๊ณจ๊ฐ•๋„์™€์˜ ๊ด€๋ จ์„ฑ

    No full text
    ๋ณด๊ฑดํ•™๊ณผ๋ฐฐ๊ฒฝ ๋ฐ ๋ชฉ์  ์ธ์Š๋ฆฐ ์ €ํ•ญ์„ฑ์€ ๊ณจ๋ฐ€๋„, ๊ทธ๋ฆฌ๊ณ  ๊ณจ๊ฐ•๋„์™€ ์—ฐ๊ด€์„ฑ์ด ์žˆ๋Š” ๊ฒƒ์œผ๋กœ ๋ณด๊ณ ๋˜์–ด ์™”๋‹ค. ๊ทธ๋Ÿฌ๋‚˜ ๋Œ€๋ถ€๋ถ„์˜ ์—ฐ๊ตฌ๋“ค์ด ๊ณจ๋ฐ€๋„๋ฅผ ๋ผˆ์˜ ๊ตฌํš ๋ณ„๋กœ ๋‚˜๋ˆ„์ง€ ์•Š๊ณ , ์ „์ฒด ๊ณจ๋ฐ€๋„๋งŒ์„ ํ‰๊ฐ€ํ–ˆ์œผ๋ฉฐ, ์ด๋ฅผ ๊ณจ๊ฐ•๋„์™€ ํ•จ๊ป˜ ์กฐ์‚ฌํ•œ ์—ฐ๊ตฌ๋„ ๋ถ€์กฑํ•˜๋‹ค. ์ธ์Š๋ฆฐ ์ €ํ•ญ์„ฑ์ด ๋ผˆ ๊ฑด๊ฐ•์— ๋ฏธ์น˜๋Š” ์ „๋ฐ˜์ ์ธ ์˜ํ–ฅ์„ ํ‰๊ฐ€ํ•˜๊ธฐ ์œ„ํ•ด์„œ๋Š” ๊ณจ๋ฐ€๋„์™€ ๊ณจ๊ฐ•๋„๋ฅผ ํ•จ๊ป˜ ์กฐ์‚ฌํ•  ํ•„์š”๊ฐ€ ์žˆ๋‹ค. ๋ณธ ์—ฐ๊ตฌ์˜ ๋ชฉ์ ์€ ํ•œ๊ตญ์˜ ์ง€์—ญ์‚ฌํšŒ ๊ฑฐ์ฃผ ์ผ๋ฐ˜ ์„ฑ์ธ ์ธ๊ตฌ๋ฅผ ๋Œ€์ƒ์œผ๋กœ ์ธ์Š๋ฆฐ ์ €ํ•ญ์„ฑ๊ณผ ๊ณจ๋ฐ€๋„, ๊ณจ๊ฐ•๋„์™€์˜ ๋…๋ฆฝ์ ์ธ ๊ด€๋ จ์„ฑ์„ ํ‰๊ฐ€ํ•˜๋Š” ๊ฒƒ์ด๋‹ค. ์—ฐ๊ตฌ ๋ฐฉ๋ฒ• ๋ณธ ์—ฐ๊ตฌ๋Š” ์ง€์—ญ์‚ฌํšŒ๊ธฐ๋ฐ˜ ์ฝ”ํ˜ธํŠธ์ธ Cardiovascular and Metabolic Disease Etiology Research Center (CMERC) ์— ์—ฐ๊ตฌ์ฐธ์—ฌ ๋™์˜ ๋ฐ ๊ธฐ๋ฐ˜์กฐ์‚ฌ๋ฅผ ๋งˆ์นœ 2,533๋ช…์˜ ์„ฑ์ธ (856๋ช…์˜ ๋‚จ์ž์™€ 1,497๋ช…์˜ ์—ฌ์ž) ์„ ๋Œ€์ƒ์œผ๋กœ ์ง„ํ–‰ํ•˜์˜€๋‹ค (ํ‰๊ท ๋‚˜์ด 49.3์„ธ). ์ธ์Š๋ฆฐ ์ €ํ•ญ์„ฑ์€ HOMA-IR ์ง€ํ‘œ๋ฅผ ์ด์šฉํ•˜์—ฌ ์ธก์ •ํ•˜์˜€๋‹ค. ๊ณจ๋ฐ€๋„๋Š” Quantitative computed tomography (QCT)๋กœ ์ธก์ •ํ•˜์˜€๊ณ , ๊ณจ๊ฐ•๋„๋Š” Compression strength index (CSI), Bending strength index (BSI), Impact strength index (ISI) ์˜ ์„ธ ๊ฐ€์ง€ ํ‰๊ฐ€๋ฐฉ๋ฒ•์„ ์ด์šฉํ•˜์—ฌ ์ธก์ •ํ•˜์˜€๋‹ค. ํ˜ผ๋ž€๋ณ€์ˆ˜๋กœ๋Š” ์—ฐ๋ น, ์ฒด์ค‘, ํก์—ฐ์ƒํƒœ, ์Œ์ฃผ์ƒํƒœ, ์‹ ์ฒดํ™œ๋™, ํ˜ˆ์ค‘ ๋น„ํƒ€๋ฏผ D ๋“ฑ์„ ๋ณด์ •ํ•˜์˜€๋‹ค. ์—ฐ๊ตฌ ๊ฒฐ๊ณผ ๋ชจ๋“  ํ˜ผ๋ž€๋ณ€์ˆ˜๋ฅผ ๋ณด์ •ํ•˜์˜€์„ ๋•Œ, ๋‚จ์ž์—์„œ๋Š” ์ธ์Š๋ฆฐ ์ €ํ•ญ์„ฑ์ด total BMD (ฮฒ=-0.029, p=0.001), trabecular BMD (ฮฒ=-0.015, p=0.000), CSI (ฮฒ=-0.286, p<0.001), ISI (ฮฒ=-0.018, p=0.004) ์™€ ํ†ต๊ณ„์ ์œผ๋กœ ์œ ์˜ํ•œ ์Œ์˜ ๊ด€๋ จ์„ฑ์„ ๋ณด์˜€์ง€๋งŒ, cortical BMD (ฮฒ=-0.015, p=0.095), BSI (ฮฒ=-0.058, p=0.946) ์™€๋Š” ํ†ต๊ณ„์ ์œผ๋กœ ์œ ์˜ํ•œ ๊ด€๋ จ์„ฑ์„ ๋ณด์ด์ง€ ์•Š์•˜๋‹ค. ์—ฌ์ž์—์„œ๋Š” ๋ชจ๋“  ํ˜ผ๋ž€๋ณ€์ˆ˜๋ฅผ ๋ณด์ •ํ•˜์˜€์„ ๋•Œ, ์ธ์Š๋ฆฐ ์ €ํ•ญ์„ฑ๊ณผ total BMD (ฮฒ=-0.017, p=0.015), CSI (ฮฒ=-0.182, p<0.001), ISI (ฮฒ=-0.017, p<0.001) ์™€ ๋…๋ฆฝ์ ์ธ ๊ด€๋ จ์„ฑ์ด ์žˆ์—ˆ์œผ๋‚˜, cortical BMD (ฮฒ=-0.012, p=0.082), trabecular BMD (ฮฒ=-0.04, p=0.174), ๊ทธ๋ฆฌ๊ณ  BSI (ฮฒ=-0.074, p=0.879) ์™€๋Š” ์—ฐ๊ด€์„ฑ์„ ๋ณด์ด์ง€ ์•Š์•˜๋‹ค. ์—ฐ๊ตฌ ๊ฒฐ๋ก  ๋ณธ ์—ฐ๊ตฌ์—์„œ, ํ•œ๊ตญ ์ง€์—ญ์‚ฌํšŒ ์ผ๋ฐ˜ ์„ฑ์ธ ์ธ๊ตฌ์—์„œ๋Š” ๋†’์€ ์ธ์Š๋ฆฐ ์ €ํ•ญ์„ฑ์„ ๊ฐ€์ง„ ์‚ฌ๋žŒ๋“ค์ด ๊ทธ๋ ‡์ง€ ์•Š์€ ์‚ฌ๋žŒ์— ๋น„ํ•ด ๋” ๋‚ฎ์€ ๊ณจ๋ฐ€๋„์™€ ๊ณจ๊ฐ•๋„๋ฅผ ๋ณด์ด๋Š” ๊ฒƒ์ด ๊ด€์ฐฐ๋˜์—ˆ๋‹ค. Introduction Insulin resistance has been reported to be associated with bone mineral density (BMD) and bone strength of femoral neck. Low BMD and bone strength are risk factors for falls or fracture and may even lead to cardiovascular disease (CVD). However, it has not been fully investigated whether compartment-specific BMD and bone strength of femur neck are associated with insulin resistance. The aim of this study was to investigate the association between insulin resistance and compartment-specific BMD and bone strength of femur neck. Methods This cross-sectional study used baseline data from the Cardiovascular and Metabolic Disease Etiology Research Center (CMERC) cohort study. A total of 2,533 study participants completed both questionnaire survey and health examinations between 2013 and 2015. After excluding participants who were taking drugs for diabetes (n=122) and osteoporosis (n=53) and who had missing data on key variables (n=5), 856 men and 1,497 women aged 30-64 years were included in this study. Cortical and trabecular BMD of femur neck were measured with quantitative computed tomography. Fasting insulin level was assayed using a RIA procedure on an immunoradiometric assay. Fasting glucose was determined by the colorimetry method. The association between insulin resistance and BMD (total bone compartment, cortical bone compartment and trabecular bone compartment) femur neck and bone strength index (compressive strength index, CSI; bending strength index, BSI; impact strength index, ISI;) was investigated by multiple linear regression model. Age, body mass index (BMI), smoking, alcohol intake, physical activity and 25-hydroxy vitamin D were considered as a covariates. Results In men, there was inversely associated with total BMD (รŸ=-0.029, p=0.001), trabecular BMD (รŸ=-0.015, p=0.000), CSI (รŸ=-0.286, p<0.001) and ISI (รŸ=-0.018, p=0.004) when adjusted for all covariates. However, the association with cortical BMD (รŸ=-0.015, p=0.095) and BSI was not significant (รŸ=0.058, p=0.946). In women, there was a negative association between HOMA-IR and total BMD (รŸ=-0.017, p=0.015), CSI (รŸ=-0.182, p<0.001) and ISI (รŸ=-0.017, p<0.001), not significant with compartment-specific BMD (Cortical: รŸ=-0.012, p=0.082, Trabecular: รŸ=-0.004, p=0.174) and BSI (รŸ=0.074, p=0.879). Conclusions High insulin resistance was negatively associated with total and trabecular BMD, CSI and ISI in men, however, there was significant association with CSI and ISI only in women.open์„

    ์ถฉ์ฒญ๋‚จ๋„ ๋‚ ์”จ๊ฒฝ์˜ ์ธ์ฆ๋“ฑ๋ก ์ถ”์ง„

    No full text
    ์ถ”์ง„๊ฒฝ๊ณผ ๋ณด๊ณ ์„œ1. ์„œ๋ก  2. ๋‚ ์”จ๊ฒฝ์˜์ธ์ฆ ํ˜„ํ™ฉ ๋ฐ ์šฐ์ˆ˜์‚ฌ๋ก€ 3. ์ธ์ฆ ์ ˆ์ฐจ ๋ฐ ์–‘์‹ 4. ์ถ”์ง„๊ฒฝ๊ณผ ๋ฐ ์ถ”์ง„๊ณ„

    First-principles calculation of electronic structure of YSZ

    No full text
    Maste

    ์ถฉ์ฒญ๋‚จ๋„ ๋‚ ์”จ๊ฒฝ์˜ ์ธ์ฆ๋“ฑ๋ก ์ถ”์ง„

    No full text
    ์ถ”์ง„๊ฒฝ๊ณผ ๋ณด๊ณ ์„œ1. ์„œ๋ก  2. ๋‚ ์”จ๊ฒฝ์˜์ธ์ฆ ํ˜„ํ™ฉ ๋ฐ ์šฐ์ˆ˜์‚ฌ๋ก€ 3. ์ธ์ฆ ์ ˆ์ฐจ ๋ฐ ์–‘์‹ 4. ์ถ”์ง„๊ฒฝ๊ณผ ๋ฐ ์ถ”์ง„๊ณ„

    ์ถฉ๋‚จ๊ธฐํ›„์ •๋ณด๋ธŒ๋ฆฌํ•‘ 15ํ˜ธ-์ถฉ์ฒญ๋‚จ๋„ 2016๋…„ 8์›” ๋”์œ„, ํ˜„ํ™ฉ๊ณผ ์ „๋ง

    No full text
    โ—Š ์˜ฌ์—ฌ๋ฆ„, ํŠนํžˆ 8์›”์€ ๊ทน์‹ฌํ•œ ๋ฌด๋”์œ„๋กœ ์˜จ์—ด์งˆํ™˜์ž ๊ธ‰์ฆ, ์–‘์‹์žฅ ํ”ผํ•ด ์ฆ๊ฐ€๋“ฑ ์‚ฌํšŒ ์ ๋ฐ˜์ ์œผ๋กœ ํญ์—ผ์— ์˜ํ•œ ํ”ผํ•ด๊ฐ€ ๋ฐœ์ƒํ•จ โ—Š ์ด๋Ÿฌํ•œ ํญ์—ผ ํ”ผํ•ด ๋ฐœ์ƒ์ด ๊ธฐํ›„๋ณ€ํ™”๋กœ ์ธํ•ด ์ง€์†๋  ๊ฒƒ์œผ๋กœ ์ „๋ง๋จ์— ๋”ฐ๋ผ์˜ฌํ•ด 8์›” ํญ์—ผํ˜„ํ™ฉ๊ณผ ๋ฏธ๋ž˜ ์ „๋ง์„ ํ†ตํ•ด ํญ์—ผ๋Œ€๋น„ ํ•„์š”์„ฑ ์ œ๊ณ ๊ฐ€ ํ•„์š”ํ•จ โ€ป ๋ณธ ๋ธŒ๋ฆฌํ•‘์€ CNI ์ธํฌ๊ทธ๋ž˜ํ”ฝ 22ํ˜ธ(2016.9.28.) ์›์‹œ์ž๋ฃŒ๋ฅผ ํ™œ์šฉํ•˜์—ฌ ์ž‘์„ฑ๋จ1. ์ถฉ์ฒญ๋‚จ๋„ 8์›” ํญ์—ผํ˜„ํ™ฉ 2. 2016๋…„ ์„œํ•ด์•ˆ ํ•ด์ˆ˜์˜จ๋„ 3. ์˜จ์—ด์งˆํ™˜์ž ๋ฐœ์ƒํ˜„ํ™ฉ 4. ์˜จ๋„์ƒ์Šน์œผ๋กœ ์ธํ•œ ์งˆ๋ณ‘ ํ™˜์ž ์ˆ˜ ์ถ”์ด 5. ๋ฏธ๋ž˜ 8์›” ๋”์œ„ ์ „๋ง-๊ธฐํ›„๋ณ€ํ™” ์‹œ๋‚˜๋ฆฌ์˜ค(RCP8.5) ๋ถ„์„ 6. ์ •์ฑ…์ œ

    ์ถฉ๋‚จ๊ธฐํ›„์ •๋ณด๋ธŒ๋ฆฌํ•‘ 11ํ˜ธ-์ถฉ์ฒญ๋‚จ๋„ ๊ธฐํ›„๋ณ€ํ™” ๊ด€๋ จ ์ •์ฑ…ํ†ตํ•ฉ ๋น„์ „์ œ์•ˆ

    No full text
    โ—Š ์ œ21์ฐจ ์œ ์—”๊ธฐํ›„๋ณ€ํ™”ํ˜‘์•ฝ ๋‹น์‚ฌ๊ตญ์ดํšŒ์—์„œ ํŒŒ๋ฆฌํ˜‘์ •์ด ์ฑ„ํƒ๋˜์–ด ๊ตญ๊ฐ€์™€ ์ง€์ž์ฒด์˜ ๋Œ€์‘์ „๋žต ์ˆ˜๋ฆฝ ํ•„์š”์„ฑ์ด ์ œ๊ธฐ๋จ์— ๋”ฐ๋ผ, โ—Š ้“ ๊ธฐํ›„๋ณ€ํ™” ๊ด€๋ จ ์‚ฐ์—…, ์—๋„ˆ์ง€, ๋…น์ƒ‰์„ฑ์žฅ์„ ํฌํ•จํ•˜๋Š” ์ •์ฑ…ํ†ตํ•ฉ ๋น„์ „(๋„ค์ด๋ฐ)์„ ์ œ์•ˆํ•˜์—ฌ, ์ถฉ์ฒญ๋‚จ๋„ ๊ธฐํ›„๋ณ€ํ™” ๋Œ€์‘์—ญ๋Ÿ‰ ๊ฐ•ํ™”๋ฅผ ์œ„ํ•œ ์ •์ฑ…๊ธฐ๋ฐ˜ ์กฐ์„ฑ์— ๊ธฐ์—ฌํ•˜๊ณ ์ž ํ•จ.1. ๊ธฐํ›„๋ณ€ํ™”ํ˜‘์ƒ ๋™ํ–ฅ 2. ๋น„์ „(๋„ค์ด๋ฐ) ์ œ์•ˆ ์ ˆ์ฐจ 3. ๊ธฐํ›„๋ณ€ํ™” ์ •์ฑ…ํ†ตํ•ฉ ๋น„์ „๊ฐœ๋ฐœ์„ ์œ„ํ•œ 10๋Œ€ ํ˜„์•ˆ๋„์ถœ 4. ๊ธฐํ›„๋ณ€ํ™” ์ •์ฑ… ํ†ตํ•ฉ ๋น„์ „(์•ˆ) ์ œ์•ˆ 5. ์ „๋ฌธ๊ฐ€ ๋ฐ ๋„๋ฏผ ์„ค๋ฌธ์„ ํ†ตํ•œ ์„ ํ˜ธ๋„ ์กฐ์‚ฌ 6. ๋น„์ „์‹คํ˜„์„ ์œ„ํ•œ ๋กœ๋“œ๋งต ์ˆ˜๋ฆฝ
    corecore